Abstract:BACKGROUND: Glioblastoma is the most common type of glioma with a high incidence and poor prognosis, and effective medical treatment remains challenging. Pseudouridine (Ψ) is the first post-transcriptional modification discovered and one of the most abundant modifications to RNA. However, the prognostic value of Ψ-related lncRNAs (ΨrLs) for glioma patients has never been systematically evaluated. This study aims to construct a risk model based on ΨrLs signature and to validate the predictive efficiency of the model.METHOD: Transcriptomic data, genomic data, and relevant clinical data of glioma patients were extracted from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA). ΨrLs with significant correlation with Ψ-related genes were identified, and univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression were used to further select biomarkers and construct a ΨrLs signature risk model. Then, the expression of lncRNAs of ΨrLs signature in multiple glioma cell lines was detected by qPCR. Further, ROC analysis, stratification analysis, correlation analysis, survival analysis, nomogram, enrichment analysis, immune infiltration analysis, chemoradiotherapy sensitivity analysis, somatic mutation, and recurrent copy number variation (CNV) analysis were used to validate the predictive efficiency of ΨrLs signature in TCGA and CGGA datasets.RESULTS: A four-lncRNA ΨrLs signature (DNAJC27-AS1, GDNF-AS1, ZBTB20-AS4, and DNMBP-AS1) risk model was constructed. By ROC analysis, stratified analysis, correlation analysis, survival analysis, and nomogram, the signature showed satisfactory predictive efficiency. Functional enrichment analysis revealed the differences in immune-related biological processes between high- and low-risk groups. Immune infiltration analysis showed that the high-risk group had lower tumor purity and higher stromal, immune and ESTIMATE scores. Mitoxantrone was identified as effective drug for low-risk group of glioma patients. Key genes in glioma development, including IDH1, EGFR, PTEN, etc., were differentially mutated between risk groups. The main recurrent CNVs in low-risk groups were 19q13.42 deletion and 7q34 amplification; 10q23.31 deletion and 12q14.1 in the high-risk group.CONCLUSIONS: Our study identified a four-lncRNA ΨrLs signature that effectively predicts the prognosis of glioma patients and may serve as a diagnostic tool. Risk scores of glioma patients generated by the signature is associated with immune-related biological processes and chemoradiotherapy sensitivity. These findings may inform the development of more targeted and effective therapies for glioma patients.

The Use of Three Long Non-Coding RNAs As Potential Prognostic Indicators of Astrocytoma

Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer

Identification of Novel Lncrna Markers in Glioblastoma Multiforme and Their Clinical Significance: A Study Based on Multiple Sequencing Data

The Use of Hsa-Mir-21, Hsa-Mir-181b and Hsa-Mir-106a As Prognostic Indicators of Astrocytoma.

Identification of 9 Serum Micrornas As Potential Noninvasive Biomarkers of Human Astrocytoma.

Development of a Novel Angiogenesis-Related Lncrna Signature to Predict the Prognosis and Immunotherapy of Glioblastoma Multiforme.

Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A lncRNA Expression Analysis

Identification of Seven Serum Micrornas from a Genome‐wide Serum Microrna Expression Profile As Potential Noninvasive Biomarkers for Malignant Astrocytomas

A Meta-Analysis of the Prognostic Value of Abnormally Expressed Lncrnas and Correlation with Clinicopathological Characteristics in Glioma

Nerve Growth Factor Expression in Astrocytoma and Cerebrospinal Fluid: a New Biomarker for Prognosis of Astrocytoma.

Prognostic and clinicopathological significance of long non-coding RNA in glioma

Identification and verification on prognostic index of glioblastoma immune-related lncRNAs

Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.

Integrated Analysis of ceRNA Network to Reveal Potential Prognostic Biomarkers for Glioblastoma

Integrative analysis of multi-omics data reveals a pseudouridine-related lncRNA signature for prediction of glioma prognosis and chemoradiotherapy sensitivity

A Three-Long Non-Coding RNA Signature Derived from the Cancer Genome Atlas Database Predicts the Survival of Patients with Head and Neck Squamous Cell Carcinoma

A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs

A Three-Lncrna Signature Derived from the Atlas of Ncrna in Cancer (TANRIC) Database Predicts the Survival of Patients with Head and Neck Squamous Cell Carcinoma.

Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma

Identification of prognostic biomarkers in glioblastoma using a long non-coding RNA-mediated, competitive endogenous RNA network

Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets